Pharmafile Logo
Pharmafocus logo
Advanced Search

Lundbeck

Showing 15 posts of 69 posts found.

Lundbeck image

Lundbeck buys Chelsea Therapeutics

May 12, 2014
Research and Development, Sales and Marketing Chelsea Therapeutics, Lundbeck

Lundbeck could pay as much as $658 million for neurological disorder specialist Chelsea Therapeutics as the firm looks to shore …

News

Lundbeck teams up with Lieber Institute

April 3, 2014
Research and Development, Sales and Marketing Astellas, AstraZeneca, Lundbeck, Pfizer, Roche, ability, brain, lieber, lilly

Lundbeck has entered into a new partnership with the Lieber Institute for Brain Development in the hope of discovering new …

News
Lundbeck image

Danish government: ‘Sue pharma firms’

January 23, 2014
Sales and Marketing Actavis, Danish, Denmark, Lundbeck, celexa

A senior figure in Denmark’s government has said that local authorities should take legal action against pharma firms which put …

News
Actelion image

Positive CHMP verdicts for Actelion and Lundbeck

October 28, 2013
Sales and Marketing Actelion, CHMP, FDA, Lundbeck

Actelion and Lundbeck both took a step closer to EU approval for two drugs seen as pivotal to their future …

News
Lundbeck image

Brintellix ‘yes’ from FDA

October 4, 2013
Sales and Marketing FDA, Lundbeck, Takeda, brintellix

Takeda Pharmaceutical Company and Lundbeck are celebrating after the FDA approved their depression treatment Brintellix – despite there being no …

News
Otsuka image

Otsuka buys Astex for $866 million

September 6, 2013
Sales and Marketing Astex, Lundbeck, Onyx, Otsuka

Otsuka Pharmaceutical is to buy UK-based Astex Pharmaceuticals in a deal that will see the Tokyo-based firm shelling out $866 …

News
Lundbeck image

Lundbeck appealing against European fine

September 2, 2013
Sales and Marketing EMA, Lundbeck, pay for delay

Lundbeck is fighting a ruling by European authorities that could see it fined nearly €100 million over a pay-for-delay deal. …

News
lundbeck image

Lundbeck/Otsuka Alzheimer’s drug improves cognition

July 17, 2013
Research and Development, Sales and Marketing Alzheimer's, Lundbeck, Otsuka

Lundbeck and partner Otsuka have posted positive Phase II results for their experimental Alzheimer’s drug. The latest data show statistically …

News

Lundbeck cuts more jobs in Europe

June 24, 2013
Manufacturing and Production, Research and Development, Sales and Marketing Lexapro, Lundbeck, cuts

Lundbeck is to cut yet more jobs in Europe as the Danish pharma firm restructures its operations to focus on …

News

Nine fined in EU pay-for-delay deals

June 20, 2013
Manufacturing and Production, Sales and Marketing EU, Lundbeck, Merck, Ranbaxy

Nine pharma firms have been handed hefty fines by the European Commission over allegations that they willingly blocked generic versions …

News

Promise for Lundbeck and Takeda’s depression drug

May 20, 2013
Research and Development, Sales and Marketing Lexapro, Lundbeck, Takeda, cymbalta, depression, lilly

Takeda and Lundbeck’s treatment for major depressive disorder has demonstrated a significant improvement in patients’ symptoms during trials. Brintellix (Vortioxetine) …

News

Lundbeck moves ahead in Q1

May 3, 2013
Sales and Marketing Lexapro, Lundbeck, Otsuka, Q1

Lundbeck’s sales and profit increase in the first three months of 2013 was due largely to one-off payments it received, …

News

Lundbeck booze pill for EU

March 1, 2013
Sales and Marketing Lundbeck, alcohol, selincro

Lundbeck’s novel pill Selincro has been given European marketing authorisation to help patients with a drink problem to cut down. …

News
hakan_bjorklund

Lundbeck elects new chairman

February 21, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Lundbeck

Lundbeck has announced it will be electing Håkan Björklund as its new chairman as Mats Pettersson steps down. Pettersson, a …

Appointment

Lexapro US loss hits Lundbeck

February 7, 2013
Sales and Marketing Danish, Lexapro, Lundbeck

The loss of US patent protection on antidepressant Lexapro has put a significant dent in Lundbeck’s financial performance for 2012. …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025